A detailed history of Albion Financial Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Albion Financial Group holds 1,395 shares of VRTX stock, worth $656,040. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,395
Previous 1,338 4.26%
Holding current value
$656,040
Previous $544,000 7.17%
% of portfolio
0.05%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$407.69 - $446.08 $23,238 - $25,426
57 Added 4.26%
1,395 $583,000
Q4 2023

Jan 26, 2024

BUY
$343.0 - $410.68 $68,600 - $82,136
200 Added 17.57%
1,338 $544,000
Q3 2023

Nov 01, 2023

SELL
$338.18 - $362.46 $676 - $724
-2 Reduced 0.18%
1,138 $395,000
Q2 2023

Jul 25, 2023

SELL
$314.42 - $351.91 $70,115 - $78,475
-223 Reduced 16.36%
1,140 $401,000
Q1 2023

Apr 18, 2023

BUY
$283.23 - $323.1 $7,080 - $8,077
25 Added 1.87%
1,363 $429,000
Q4 2022

Feb 03, 2023

SELL
$285.76 - $321.48 $14,002 - $15,752
-49 Reduced 3.53%
1,338 $386,000
Q3 2022

Oct 27, 2022

BUY
$273.83 - $305.53 $10,953 - $12,221
40 Added 2.97%
1,387 $402,000
Q2 2022

Jul 29, 2022

SELL
$234.96 - $292.55 $123,119 - $153,296
-524 Reduced 28.01%
1,347 $380,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $66,868 - $78,812
302 Added 19.25%
1,871 $488,000
Q4 2021

Feb 15, 2022

SELL
$177.01 - $223.45 $71,335 - $90,050
-403 Reduced 20.44%
1,569 $345,000
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $937 - $1,105
-5 Reduced 0.25%
1,972 $398,000
Q4 2020

Feb 19, 2021

SELL
$207.01 - $276.09 $2,277 - $3,036
-11 Reduced 0.55%
1,977 $467,000
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $508,232 - $602,562
1,988 New
1,988 $541,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Albion Financial Group Portfolio

Follow Albion Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Albion Financial Group , based on Form 13F filings with the SEC.

News

Stay updated on Albion Financial Group with notifications on news.